ReviewClinical cancer research : an official journal of the American Association for Cancer Research2006
Treatment-related osteoporosis in men with prostate cancer.
Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 62 citations in OpenAlex.
- Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2011Trial
- A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer.Yonsei medical journal · 2007Trial
- The iron-ferroptosis axis in bone homeostasis: a potential complementary pathway for osteoporosis in endometriosis.European journal of medical research · 2026Review
- Effects of silybin on triptorelin-induced bone metabolic abnormalities in prostate cancer revealed based on TMT-based proteomics.PloS one · 2026Article
- Inhibitors of the transactivation domain of androgen receptor as a therapy for prostate cancer.Steroids · 2024Review
- Intra-pituitary follicle-stimulating hormone signaling regulates hepatic lipid metabolism in mice.Nature communications · 2023Article
- Review
- The Relationship Between Bone and Reproductive Hormones Beyond Estrogens and Androgens.Endocrine reviews · 2021Review
- Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer.Prostate cancer and prostatic diseases · 2018Article
- Article
- Bone mineral density measurements of the proximal femur from routine contrast-enhanced MDCT data sets correlate with dual-energy X-ray absorptiometry.European radiology · 2013Article
- Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid.Therapeutic advances in urology · 2012Article
- Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy.International journal of endocrinology · 2012Article
- Disruption of androgen and estrogen receptor activity in prostate cancer by a novel dietary diterpene carnosol: implications for chemoprevention.Cancer prevention research (Philadelphia, Pa.) · 2010Article
- Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women.Clinical interventions in aging · 2008Review
- [Prevention of osteoporosis--important for the urologist?].Der Urologe. Ausg. A · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The intended therapeutic effect of gonadotropin-releasing hormone (GnRH) agonists is hypogonadism, a major cause of acquired osteoporosis in men. Consistent with this observation, GnRH agonists increase bone turnover and decrease bone mineral density, a surrogate for fracture risk. Large claims-based analyses and other retrospective studies provide compelling evidence that GnRH agonists increase risk of clinical fractures. Estrogens play a central role in homeostasis of the normal male skeleton, and estrogen deficiency rather than testosterone deficiency seems to be primarily responsible for the adverse skeletal effects of GnRH agonists. In randomized controlled trials, bisphosphonates (pamidronate and zoledronic acid) and selective estrogen receptor modulators (raloxifene and toremifene) increased bone mineral density in GnRH agonist-treated men. Two ongoing large randomized placebo-controlled studies will prospectively define fracture outcomes in men with prostate cancer and assess the efficacy of novel pharmacologic interventions (AMG162, toremifene) during GnRH agonist treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.